Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biologics Reached Record Share Of Novel Approvals In 2009

Executive Summary

The pharmaceutical industry's strategy of looking to biologics as a source of innovation is clearly demonstrated in FDA's novel approvals in 2009
Advertisement

Related Content

Follow-on Biologic's Day Will Come - Post 2015, Teva Says
Stelara Clears FDA; Different Class, But REMS Looks Similar To TNF Blockers
H1N1 Vaccines Get Green Light In U.S., But Is Anything Else Needed?
Seventh Statin Appoved: Kowa Will Take A Niche Strategy For Livalo
Big Pharma’s March Into Biotech Could Make Big Biologics A Big ’09 Theme
Big Pharma’s March Into Biotech Could Make Big Biologics A Big ’09 Theme
CDER Closes Out 2008 With 24 Novel Approvals, But Few Are First In Class
CDER Closes Out 2008 With 24 Novel Approvals, But Few Are First In Class
Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps
Big Pharma's Leap into Biologics: Bridging both Scientific and Cultural Gaps

Topics

Advertisement
UsernamePublicRestriction

Register

PS051835

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel